Results 141 to 150 of about 72,525 (247)

The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines

Haematologica, 2006
We evaluated the effect of the human immunodeficiency virus (HIV) protease inhibitor saquinavir on the imatinib-sensitive and imatinib-resistant chronic myelogenous leukemia cell lines.
F Timeus, N Crescenzio, E Ricotti, A Doria, D Bertin, G Saglio, PA Tovo   +6 more
doaj  

Neurofibromatosis Type 1 Tumor Involving the Anterosuperior Mediastinum With a Rare c.147C>G Germline Mutation: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that affects multiple organ systems, most commonly the skin, peripheral nerves, and skeletal system. However, involvement of the anterior mediastinum is rare and has been sporadically reported in the literature.
Yuhao Qi, Shenghai Wang, Zhaokun Sun, Jianhua Du, Jun Li   +4 more
wiley   +1 more source

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation

Haematologica, 2006
Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions.
M Weisser, J Tischer, S Schnittger, C Schoch, G Ledderose, HJ Kolb   +5 more
doaj  

Breast Fibromatosis: Clinical and Pathological Insights From Two Case Reports

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Breast fibromatosis is a benign, locally aggressive spindle‐cell tumor mimicking carcinoma. We report two cases in patients aged 15 and 61 years, highlighting its wide age range. Accurate histopathology prevents overtreatment. Modern management emphasizes individualized care, including active surveillance, complete surgical excision when ...
Vahid Soleimani, Behnaz Jahanbin, Aysan Nozheh   +2 more
wiley   +1 more source

Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors. [PDF]

J Gastrointest Oncol
Janczewski LM.
europepmc   +1 more source

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

, 2015
Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Balakumar K, Franklin G, Sheeba CJ, Revina AM, Khandelwal VKM, Prakash J, Marslin G   +6 more
core  

Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 931-933, October 2026.
Paige Muir, Mohammad Bahmanyar, Hamish Nicolson, Hayley Merkeley   +3 more
wiley   +1 more source

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open‐label, phase 2 trial

Cancer, Volume 132, Issue 17, 1 September 2026.
Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony‐stimulating factor 1 (CSF1) gene. Patients report substantial pain, stiffness, and declining physical function; those whose disease is not amenable to surgery require systemic therapy.
Silvia Stacchiotti, Jean‐Yves Blay, Piotr Rutkowski, Hans Gelderblom, Alejandro Falcón, Axel Le Cesne, Jayesh Desai, Emanuela Palmerini, César Serrano, Kristen N. Ganjoo, Gina Z. D’Amato, Christopher W. Ryan, Breelyn A. Wilky, Virginia Ferraresi, Ramy Saleh, Vinod Ravi, Albiruni Abdul Razak, Antonio Casado Herráez, Mahbubl Ahmed, Nicholas M. Bernthal, Michiel van de Sande, Mehdi Brahmi, Bartlomiej Szostakowski, Jasmine Sen, Nicholas A. Zeringo, Brooke Harrow, Supraja Narasimhan, Amanda Saunders, Maitreyi G. Sharma, Matthew L. Sherman, Andrew J. Wagner, William D. Tap   +31 more
wiley   +1 more source

Adjuvant treatment of gastrointestinal stromal tumors (GIST)-state of the art, controversies, and future directions. [PDF]

ESMO Gastrointest Oncol
Scheuble AM, Lordick F, Maki RG.
europepmc   +1 more source

The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study. [PDF]

J Gastrointest Oncol
Shou C, Yang W, Wang X, Zhang Q, Yu J, Liang T.   +5 more
europepmc   +1 more source